Jonathan R. Young, Luke N. Ledbetter, Julie A. Ressler, Mark S. Shiroishi, Joanne E. Mortimer, Daniel Schmolze, Mariko Fitzgibbons, Bihong T. Chen
{"title":"动态增强灌注MR的体积转移常数（Ktrans）与乳腺癌脑转移瘤HER2状态之间的关系","authors":"Jonathan R. Young, Luke N. Ledbetter, Julie A. Ressler, Mark S. Shiroishi, Joanne E. Mortimer, Daniel Schmolze, Mariko Fitzgibbons, Bihong T. Chen","doi":"10.1002/cnr2.70354","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>With the development of new human epidermal growth factor 2 (HER2)-targeting therapies, a non-invasive method of determining the HER2 status of breast cancer brain metastases can be of great clinical value, particularly given the risks of brain biopsy and the possibility of discordance between HER2 status of the primary breast cancer and the brain metastasis.</p>\n </section>\n \n <section>\n \n <h3> Aims</h3>\n \n <p>The purpose of this study was to assess whether the volume transfer constant (Ktrans) from dynamic contrast-enhanced (DCE) perfusion brain MR could assist in identifying the HER2 status of breast cancer brain metastases.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>With IRB approval for this retrospective study, we searched the electronic medical record at the City of Hope Comprehensive Cancer Center to identify all histopathologically proven breast cancer brain metastases with both preoperative DCE perfusion brain MR and HER2 assessment of the resected/biopsied brain specimens at the City of Hope Comprehensive Cancer Center from 2011-2022. Mann-Whitney tests were used to compare the Ktrans of the breast cancer brain metastases.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>There were 9 women in our study cohort with a mean age of 55 years. Our cohort was comprised of a total of 9 breast cancer brain metastases, 3 of which were HER2-positive, 6 of which were HER2-negative. The Ktrans of HER2-positive breast cancer brain metastases was significantly greater than the Ktrans of HER2-negative breast cancer brain metastases (0.09 min<sup>−1</sup> vs 0.02 min<sup>−1</sup>, U = 18.00, <i>p</i> = 0.024).</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>Ktrans may help to differentiate HER2-positive from HER2-negative breast cancer brain metastases, if validated in a large prospective, multi-center trial.</p>\n </section>\n </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 10","pages":""},"PeriodicalIF":1.9000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70354","citationCount":"0","resultStr":"{\"title\":\"Association Between the Volume Transfer Constant (Ktrans) From Dynamic Contrast-Enhanced Perfusion MR and HER2 Status in Breast Cancer Brain Metastases\",\"authors\":\"Jonathan R. Young, Luke N. Ledbetter, Julie A. Ressler, Mark S. Shiroishi, Joanne E. Mortimer, Daniel Schmolze, Mariko Fitzgibbons, Bihong T. Chen\",\"doi\":\"10.1002/cnr2.70354\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Background</h3>\\n \\n <p>With the development of new human epidermal growth factor 2 (HER2)-targeting therapies, a non-invasive method of determining the HER2 status of breast cancer brain metastases can be of great clinical value, particularly given the risks of brain biopsy and the possibility of discordance between HER2 status of the primary breast cancer and the brain metastasis.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Aims</h3>\\n \\n <p>The purpose of this study was to assess whether the volume transfer constant (Ktrans) from dynamic contrast-enhanced (DCE) perfusion brain MR could assist in identifying the HER2 status of breast cancer brain metastases.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods</h3>\\n \\n <p>With IRB approval for this retrospective study, we searched the electronic medical record at the City of Hope Comprehensive Cancer Center to identify all histopathologically proven breast cancer brain metastases with both preoperative DCE perfusion brain MR and HER2 assessment of the resected/biopsied brain specimens at the City of Hope Comprehensive Cancer Center from 2011-2022. Mann-Whitney tests were used to compare the Ktrans of the breast cancer brain metastases.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>There were 9 women in our study cohort with a mean age of 55 years. Our cohort was comprised of a total of 9 breast cancer brain metastases, 3 of which were HER2-positive, 6 of which were HER2-negative. The Ktrans of HER2-positive breast cancer brain metastases was significantly greater than the Ktrans of HER2-negative breast cancer brain metastases (0.09 min<sup>−1</sup> vs 0.02 min<sup>−1</sup>, U = 18.00, <i>p</i> = 0.024).</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusion</h3>\\n \\n <p>Ktrans may help to differentiate HER2-positive from HER2-negative breast cancer brain metastases, if validated in a large prospective, multi-center trial.</p>\\n </section>\\n </div>\",\"PeriodicalId\":9440,\"journal\":{\"name\":\"Cancer reports\",\"volume\":\"8 10\",\"pages\":\"\"},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2025-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70354\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/cnr2.70354\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer reports","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cnr2.70354","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
随着新的人表皮生长因子2 （HER2）靶向治疗的发展，一种非侵入性的方法来确定乳腺癌脑转移的HER2状态可能具有很大的临床价值，特别是考虑到脑活检的风险和原发性乳腺癌的HER2状态与脑转移的可能不一致。目的本研究的目的是评估动态对比增强（DCE）灌注脑MR的体积转移常数（Ktrans）是否有助于识别乳腺癌脑转移灶的HER2状态。方法：在获得IRB批准的这项回顾性研究中，我们检索了希望之城综合癌症中心的电子病历，通过2011-2022年期间希望之城综合癌症中心切除/活检脑标本的术前DCE灌注脑MR和HER2评估，确定所有组织病理学证实的乳腺癌脑转移灶。曼-惠特尼试验用于比较乳腺癌脑转移的Ktrans。结果我们的研究队列中有9名女性，平均年龄为55岁。我们的队列共包括9例乳腺癌脑转移患者，其中3例her2阳性，6例her2阴性。her2阳性乳腺癌脑转移灶的Ktrans显著高于her2阴性乳腺癌脑转移灶的Ktrans （0.09 min−1 vs 0.02 min−1,U = 18.00, p = 0.024）。结论Ktrans可能有助于区分her2阳性和her2阴性乳腺癌脑转移灶，如果在一项大型前瞻性多中心试验中得到证实。
Association Between the Volume Transfer Constant (Ktrans) From Dynamic Contrast-Enhanced Perfusion MR and HER2 Status in Breast Cancer Brain Metastases
Background
With the development of new human epidermal growth factor 2 (HER2)-targeting therapies, a non-invasive method of determining the HER2 status of breast cancer brain metastases can be of great clinical value, particularly given the risks of brain biopsy and the possibility of discordance between HER2 status of the primary breast cancer and the brain metastasis.
Aims
The purpose of this study was to assess whether the volume transfer constant (Ktrans) from dynamic contrast-enhanced (DCE) perfusion brain MR could assist in identifying the HER2 status of breast cancer brain metastases.
Methods
With IRB approval for this retrospective study, we searched the electronic medical record at the City of Hope Comprehensive Cancer Center to identify all histopathologically proven breast cancer brain metastases with both preoperative DCE perfusion brain MR and HER2 assessment of the resected/biopsied brain specimens at the City of Hope Comprehensive Cancer Center from 2011-2022. Mann-Whitney tests were used to compare the Ktrans of the breast cancer brain metastases.
Results
There were 9 women in our study cohort with a mean age of 55 years. Our cohort was comprised of a total of 9 breast cancer brain metastases, 3 of which were HER2-positive, 6 of which were HER2-negative. The Ktrans of HER2-positive breast cancer brain metastases was significantly greater than the Ktrans of HER2-negative breast cancer brain metastases (0.09 min−1 vs 0.02 min−1, U = 18.00, p = 0.024).
Conclusion
Ktrans may help to differentiate HER2-positive from HER2-negative breast cancer brain metastases, if validated in a large prospective, multi-center trial.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
